Skip to search formSkip to main contentSkip to account menu

Quisinostat

An orally bioavailable, second-generation, hydroxamic acid-based inhibitor of histone deacetylase (HDAC) with potential antineoplastic activity. HDAC… 
National Institutes of Health

Related topics

Related topics

10 relations
ApoptosisChromatin Structural ProcessFree Radical FormationGene Expression Regulation

Narrower (1)

JNJ 26481585

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Selective inhibition of cancer cell self-renewal through a Quisinostat-histone H1.0 axis
Continuous cancer growth is driven by subsets of self-renewing malignant cells. Targeting of uncontrolled self-renewal through… 
2017
2017
Pharmacokinetic (PK) profile of quisinostat in combination with gemcitabine and cisplatin in patients (pts) with non-small cell lung cancer (NSCLC) or paclitaxel and carboplatin in pts with NSCLC or…
2016
2016
Abstract 4030: Epigenetic induction of MHC-II pathway expression in murine ovarian cancer cell line
INTRODUCTION This study evaluated the potential of epigenetic treatments to induce the expression of the MHC-II antigen… 
2014
2014
Abstract 643: The histone deacetylase inhibitor Quisinostat augments the anti-tumor reponses of T-cells: Implications in adoptive cell therapy
Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA It has become increasingly clear that histone deacetylases… 
2014
2014
826: Primary T-prolymphocytic leukemia (T-PLL) cells are sensitive to BCL-2 and HDAC inhibitors: Results from high-throughput ex vivo drug testing
2013
2013
Phase 1b Dose Escalation Study Of Oral Quisinostat, a Histone Deacetylase Inhibitor (HDACi), In Combination With Velcade (Bortezomib) and Dexamethasone For Patients With Relapsed Multiple Myeloma (MM…
Background HDACi inhibits aggresome function by acetylation of the tubulin-dynein complex that transports unfolded proteins via… 
2013
2013
Étude rétrospective évaluant l’efficacité de l’électrostimulation sur la douleur dans la prise en charge des ulcères de jambe
2013
2013
Traitement des angiomes plans de l’enfant par laser à colorant pulsé et timolol gel
2013
2013
Phase Ib dose escalation study of oral quisinostat, a histone deacetylase inhibitor, in combination with bortezomib and dexamethasone for patients with relapsed multiple myeloma.
2013
2013
Essai multicentrique de phase 2 évaluant le quisinostat oral (inhibiteur d’histone déacétylase, iHDAC) chez des patients atteints de lymphome T cutané (LTC) au stade IB-IVA déjà traité
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)